Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® (iptacopan ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and ...

Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Thursday. The brokerage set a “sell” rating on the ...

The phase 3 trial was carried out in patients with paroxysmal nocturnal hemoglobinuria (PNH), one if the indications on Soliris' label, and showed that there was no difference between the ...

Jeremy Crosby at B&B Sports in Hutchinson has been on the phone with an important customer lately, trying to help make a wish come true. He and Tyson Karsky, a 17-year-old from Clinton, went ...

The drug was approved by the agency in 2023 as a treatment for paroxysmal nocturnal hemoglobinuria, winning the title of the first oral monotherapy approved for the rare blood disorder.

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

Urine microscopy is an important adjunct to the urinalysis. The findings of cells, casts or crystals can aid in urinalysis interpretation and in making a more accurate diagnosis. Since the formed ...